What to Expect From Stryker’s Next Quarterly Earnings Report


Stryker Corp_ HQ sign -by Sundry Photography via Shutterstock
Stryker Corp_ HQ sign -by Sundry Photography via Shutterstock

Portage, Michigan-based Stryker Corporation (SYK) operates as a medical technology company that develops, manufactures, and markets specialty surgical and medical products. Valued at $148.7 billion by market cap, the company’s products include implants, surgical, neurologic, ear, nose and throat and interventional pain equipment, endoscopic, surgical navigation, digital imaging systems, as well as patient handling and emergency medical equipment. The Medtech giant is expected to announce its fiscal second-quarter earnings for 2025 after the market closes on Thursday, Jul. 31.

Ahead of the event, analysts expect SYK to report a profit of $3.06 per share on a diluted basis, up 8.9% from $2.81 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.

For the full year, analysts expect SYK to report EPS of $13.35, up 9.5% from $12.19 in fiscal 2024. Its EPS is expected to rise 11% year over year to $14.82 in fiscal 2026.

www.barchart.com
www.barchart.com

SYK stock has outperformed the S&P 500 Index’s ($SPX) 12.3% gains over the past 52 weeks, with shares up 16.8% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund’s (XLV) 6.5% dip over the same time frame.

www.barchart.com
www.barchart.com

SYK thrives on growing procedural volumes and strong capital product demand.

On May 1, SYK reported its Q1 results, and its shares closed up more than 1% in the following trading session. Its adjusted EPS of $2.84 exceeded Wall Street expectations of $2.73. The company’s revenue was $5.9 billion, exceeding Wall Street forecasts of $5.7 billion. SYK expects full-year adjusted EPS in the range of $13.20 to $13.45.

Analysts’ consensus opinion on SYK stock is bullish, with a “Strong Buy” rating overall. Out of 28 analysts covering the stock, 19 advise a “Strong Buy” rating, two suggest a “Moderate Buy,” and seven give a “Hold.” SYK’s average analyst price target is $431.77, indicating a potential upside of 10.1% from the current levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

More From Author

Best Biwa Hayahide build guide in Umamusume: Pretty Derby

Somi Lee seizes one-stroke lead at Evian Championship

Leave a Reply

Your email address will not be published. Required fields are marked *